These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38124774)

  • 21. Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.
    Weinke T; Edte A; Schmitt S; Lukas K
    Z Gesundh Wiss; 2010 Aug; 18(4):367-374. PubMed ID: 21124645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network.
    Sun X; Wei Z; Lin H; Jit M; Li Z; Fu C
    J Infect; 2021 Feb; 82(2):253-260. PubMed ID: 33359014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
    Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
    J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality.
    Brisson M
    Can J Public Health; 2008; 99(5):383-6. PubMed ID: 19009921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD; Pfeil AM
    Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries.
    Lukas K; Edte A; Bertrand I
    Z Gesundh Wiss; 2012 Aug; 20(4):441-451. PubMed ID: 22822293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.
    Gauthier A; Breuer J; Carrington D; Martin M; Rémy V
    Epidemiol Infect; 2009 Jan; 137(1):38-47. PubMed ID: 18466661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nutritional factors in herpes zoster, postherpetic neuralgia, and zoster vaccination.
    Chen JY; Chang CY; Lin YS; Hu ML
    Popul Health Manag; 2012 Dec; 15(6):391-7. PubMed ID: 23088666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
    Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
    Gater A; Uhart M; McCool R; Préaud E
    BMC Public Health; 2015 Feb; 15():193. PubMed ID: 25880058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy.
    Parruti G; Tontodonati M; Rebuzzi C; Polilli E; Sozio F; Consorte A; Agostinone A; Di Masi F; Congedo G; D'Antonio D; Granchelli C; D'Amario C; Carunchio C; Pippa L; Manzoli L; Volpi A;
    BMC Med; 2010 Oct; 8():58. PubMed ID: 20937086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
    Szucs TD; Kressig RW; Papageorgiou M; Kempf W; Michel JP; Fendl A; Bresse X
    Hum Vaccin; 2011 Jul; 7(7):749-56. PubMed ID: 21606685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
    Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
    Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cross-sectional survey of work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire.
    Johnson KD; Brenneman SK; Newransky C; Sheffler-Collins S; Becker LK; Belland A; Acosta CJ
    BMC Health Serv Res; 2018 Aug; 18(1):662. PubMed ID: 30144806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
    Johnson RW
    Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.